Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)Peter Thuss‐Patience, Peter Reichardt, Albrecht Kretzschmar et al.|European Journal of Cancer|2011Cited by 615
Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)Peter Thuss‐Patience, Peter Reichardt, Albrecht Kretzschmar et al.|Journal of Clinical Oncology|2009Cited by 68
Trans-arterial embolization for treatment of acute lower gastrointestinal bleeding—a multicenter analysisClarissa Hosse, Timo Alexander Auer, M Moos et al.|European Radiology|2024Cited by 21
MR Imaging Biomarkers for the Prediction of Outcome after Radiofrequency Ablation of Hepatocellular Carcinoma: Qualitative and Quantitative Assessments of the Liver Imaging Reporting and Data System and Radiomic FeaturesAlexandra Petukhova-Greenstein, Julius Chapiro, Tal Zeevi et al.|Journal of Vascular and Interventional Radiology|2022Cited by 14
6504 Survial advantage for irinotecan versus best supportive care (BSC) as 2nd-line chemotherapy in gastric cancer – a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)P. Thuss-Patience, Peter Reichardt, Bernhard Gebauer et al.|European Journal of Cancer Supplements|2009Cited by 9